Upload Avatar (500 x 500)
Ying Liu
liu_ying@fudan.edu.cn
Chinese, English
Shanghai
Fudan University
Basic Medical Sciences
  • 2022.7 - Present - Editorial Board Member, Brain Pathology
  • 2022.11 - Present - Deputy Leader, Pathological Diagnosis Group, ALS Brain Bank Alliance, East China
  • 2018.01 - Present - Member, Neuropathology Group, Pathology Branch, Chinese Medical Association
  • 2018.10 - Present - Secretary, Pathology Teaching Committee, Chinese Medical Association
Glioma Angiogenesis
Glioma Metabolism and Tumor Proliferation
  • Nuclear Translocation of LDHA Promotes the Catabolism of BCAAs to Sustain GBM Cell Proliferation through the TxN Antioxidant Pathway, Li Z, Gu Z, Wang L, Guan Y, Lyu Y, Zhang J, Wang Y, Wang X, Xiong J, Liu Y, 2023
  • ROS attenuates TET2-dependent ZO-1 epigenetic expression in cerebral vascular endothelial cells, Lan Wang, Bei Mao, Keyang Fan, Renqiang Sun, Jialong Zhang, Huazheng Liang, Ying Liu, 2022
  • Safety and Efficacy of Hypofractionated Stereotactic Radiotherapy with Anlotinib Targeted Therapy for Glioblastoma at the First Recurrence: A Preliminary Report, Guan Y, Li J, Gong X, Zhu H, Li C, Mei G, Liu X, Pan L, Dai J, Wang Y, Wang E, Liu Y, Wang X, 2022
  • Reduction in immune cell number and loss of 5hmC are associated with lesion grade in cervical carcinogenesis, Yang X, Shen X, Li Z, Li W, Liu Y, 2021
  • The Hippo-TAZ axis mediates vascular endothelial growth factor C in glioblastoma-derived exosomes to promote angiogenesis, Wang Z, Yuan Y, Ji X, Xiao X, Li Z, Yi X, Zhu Y, Guo T, Wang Y, Chen L, Liu Y, 2021
  • TAZ Expression on Endothelial Cells Is Closely Related to Blood Vascular Density and VEGFR2 Expression in Astrocytomas, Chenyue Xu, Luning Mao, Ji Xiong, Jianbo Wen, Yin Wang, Daoying Geng, Ying Liu, 2019
  • Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy, Xu YP, Lv L, Liu Y, Smith MD, Li WC, Tan XM, Cheng M, Li Z, Bovino M, Aubé J, Xiong Y, 2019
  • Nuclear lactate dehydrogenase A senses ROS to produce α-hydroxybutyrate for HPV-induced cervical tumor growth, Yuan Liu, Ji-Zheng Guo, Ying Liu, Kui Wang, Wencheng Ding, Hui Wang, Xiang Liu, Shengtao Zhou, Xiao-Chen Lu, Hong-Bin Yang, Chenyue Xu, Wei Gao, Li Zhou, Yi-Ping Wang, Weiguo Hu, Yuquan Wei, Canhua Huang, Qun-Ying Lei, 2018
  • Adenosine A2A receptor agonist ameliorates EAE and correlates with Th1 cytokine-induced blood brain barrier dysfunction via suppression of MLCK signaling pathway, Ying Liu, Marwan Alahiri, Bianca Ulloa, Boxun Xie, Saud A. Sadiq, 2018
  • Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation, Hui Yang, Ying Liu, Feng Bai, Jing-Ye Zhang, Sheng-Hong Ma, Jing Liu, Zu-De Xu, Hong-Guang Zhu, Zhi-Qiang Ling, Dan Ye, Kun-Liang Guan, Yue Xiong, 2013
  • IDH1 mutations inhibit multiple α-ketoglutarate-dependent dioxygenase activities in astroglioma, Liu Y, Jiang W, Liu J, Zhao S, Xiong J, Mao Y, Wang Y, 2012
  • Quantitative analysis of neovascular permeability in glioma by dynamic contrast-enhanced MR imaging, Jia Z, Geng D, Xie T, Zhang J, Liu Y, 2012
  • Adenosine A2a receptor induces GDNF expression by Stat3 signal in vitro, Ke Rong-Hu, Xiong Ji, Liu Ying, 2012
  • Oncometabolite 2-Hydroxyglutarate is a Competitive Inhibitor of a-Ketoglutarate-Dependent Dioxygenases, Wei Xu, Hui Yang, Ying Liu, Ying Yang, Ping Wang, Se-Hee Kim, Shinsuke Ito, Chen Yang, Pu Wang, Meng-Tao Xiao, Li-xia Liu, Wen-qing Jiang, Jing Liu, Jin-ye Zhang, Bin Wang, Stephen Frye, Yi Zhang, Yan-hui Xu, Qun-ying Lei, Kun-Liang Guan, Shi-min Zhao, Yue Xiong, 2011
  • Inclusion-positive cell types in adult-onset intranuclear inclusion body disease: implications for clinical diagnosis, Ying Liu, Maya Mimuro, Mari Yoshida, Yoshio Hashizume, Hisayoshi Niwa, Shinichi Miyao, Nobuko Ujihira, Hiroyasu Akatsu, 2008
  • 实用病理学技术及特染方法, 刘颖, 刘秀萍, 2022
  • 现代组织化学原理及技术, 刘颖,朱虹光, 2017
  • 病理学实验教程, 张志刚,刘颖, 2012
Glioma Angiogenesis Tumor Proliferation Metabolism Cancer Brain Pathology Research Neuroscience

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.